M 281

Drug Profile

M 281

Alternative Names: anti-FcRn monoclonal antibody - Momenta Pharmaceuticals; M281

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 05 Jan 2018 Momenta Pharmaceuticals plans a proof-of-concept trial in second half of 2018
  • 05 Jan 2018 Efficacy and adverse events data from a phase I trial in Autoimmune disorders released by Momenta Pharmaceuticals
  • 15 Aug 2017 Momenta Pharmaceuticals completes a phase I trial in Autoimmune disorders (In volunteers) in Netherlands (Parenteral) (NCT02828046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top